European set up at Asian price levels: what more do you need ?

By Dr. Emilie Vaquer, Eurofins ADME BIOANALYSES, France, emilievaquer@eurofins.com

Quality, timelines and costs are of the highest importance for the market of generic drugs. Eurofins ADME BIOANALYSES has adapted its services to clients’ needs and offers an attractive and full package to complete successfully bioequivalence studies.

Today, Eurofins has strong partnerships with several global clinical centers: in France with Eurofins Optimed, in Europe and worldwide. Clinical trials are performed in close collaboration with these trustworthy and successful experienced clinical units, which are recognised by International authorities, such as FDA, Afssaps, WHO, MHRA.

All clinical trials comply with applicable Good Clinical Practices (GCP) and safety measures. These units are managed by efficient and experienced teams of clinical research professionals who give advice on the most relevant study design in line with the latest regulation and propose full clinical services, including study document writing and submission as well as medical support. These clinical units have a large pool of healthy volunteers and specific populations (diabetic, dyslipidemic, overweight, high blood pressure subjects). The largest unit has a capacity of 130 beds.

The samples collected during clinical trials are analysed and pharmacokinetics parameters are calculated by Eurofins, using fully validated Software.With this new full package, Eurofins ensures high quality and cost effective opportunities for drug development.

Contact: bioanalysis@eurofins.com